Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 323

1.

Urothelial Cancers with Small Cell Variant Histology Have Confirmed High Tumor Mutational Burden, Frequent TP53 and RB Mutations, and a Unique Gene Expression Profile.

Hoffman-Censits J, Choi W, Pal S, Trabulsi E, Kelly WK, Hahn NM, McConkey D, Comperat E, Matoso A, Cussenot O, Cancel-Tassin G, Fong MHY, Ross J, Madison R, Ali S.

Eur Urol Oncol. 2020 Feb 12. pii: S2588-9311(19)30168-3. doi: 10.1016/j.euo.2019.12.002. [Epub ahead of print]

PMID:
32061548
2.

Naturally-Occurring Invasive Urothelial Carcinoma in Dogs, a Unique Model to Drive Advances in Managing Muscle Invasive Bladder Cancer in Humans.

Knapp DW, Dhawan D, Ramos-Vara JA, Ratliff TL, Cresswell GM, Utturkar S, Sommer BC, Fulkerson CM, Hahn NM.

Front Oncol. 2020 Jan 21;9:1493. doi: 10.3389/fonc.2019.01493. eCollection 2019. Review.

3.

Histologic Subtypes and Response to PD-1/PD-L1 Blockade in Advanced Urothelial Cancer: A Retrospective Study.

Miller NJ, Khaki AR, Diamantopoulos LN, Bilen MA, Santos V, Agarwal N, Morales-Barrera R, Devitt M, Nelson A, Hoimes CJ, Shreck E, Assi H, Gartrell BA, Sankin A, Rodriguez-Vida A, Lythgoe M, Pinato DJ, Drakaki A, Joshi M, Velho PI, Hahn N, Liu S, Buznego LA, Duran I, Moses M, Jain J, Murgic J, Barata P, Tripathi A, Zakharia Y, Galsky MD, Sonpavde G, Yu EY, Lyman GH, Grivas P.

J Urol. 2020 Jan 23:101097JU0000000000000761. doi: 10.1097/JU.0000000000000761. [Epub ahead of print]

PMID:
31971495
4.

Reply by Authors.

Margulis V, Puligandla M, Trabulsi EJ, Plimack ER, Kessler ER, Matin SF, Godoy G, Alva A, Hahn NM, Carducci MA, Hoffman-Censits J; and Collaborators; and Collaborators.

J Urol. 2020 Jan 22:101097JU000000000000064402. doi: 10.1097/JU.0000000000000644.02. [Epub ahead of print] No abstract available.

PMID:
31967495
5.

Single cell and genetic analyses reveal conserved populations and signaling mechanisms of gastrointestinal stromal niches.

Kim JE, Fei L, Yin WC, Coquenlorge S, Rao-Bhatia A, Zhang X, Shi SSW, Lee JH, Hahn NA, Rizvi W, Kim KH, Sung HK, Hui CC, Guo G, Kim TH.

Nat Commun. 2020 Jan 17;11(1):334. doi: 10.1038/s41467-019-14058-5.

6.

Multiple sclerosis.

Klocke S, Hahn N.

Ment Health Clin. 2019 Nov 27;9(6):349-358. doi: 10.9740/mhc.2019.11.349. eCollection 2019 Nov.

7.

Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with checkpoint inhibitors.

Khaki AR, Li A, Diamantopoulos LN, Bilen MA, Santos V, Esther J, Morales-Barrera R, Devitt M, Nelson A, Hoimes CJ, Shreck E, Assi H, Gartrell BA, Sankin A, Rodriguez-Vida A, Lythgoe M, Pinato DJ, Drakaki A, Joshi M, Isaacsson Velho P, Hahn N, Liu S, Alonso Buznego L, Duran I, Moses M, Jain J, Murgic J, Baratam P, Barata P, Tripathi A, Zakharia Y, Galsky MD, Sonpavde G, Yu EY, Shankaran V, Lyman GH, Grivas P.

Cancer. 2019 Dec 12. doi: 10.1002/cncr.32645. [Epub ahead of print]

PMID:
31829450
8.

Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery in Patients with High Grade Upper Tract Urothelial Carcinoma.

Margulis V, Puligandla M, Trabulsi EJ, Plimack ER, Kessler ER, Matin SF, Godoy G, Alva A, Hahn NM, Carducci MA, Hoffman-Censits J; and Collaborators; and Collaborators.

J Urol. 2019 Nov 8:101097JU0000000000000644. doi: 10.1097/JU.0000000000000644. [Epub ahead of print]

PMID:
31702432
9.

The Orphan Cytokine Receptor CRLF3 Emerged With the Origin of the Nervous System and Is a Neuroprotective Erythropoietin Receptor in Locusts.

Hahn N, Büschgens L, Schwedhelm-Domeyer N, Bank S, Geurten BRH, Neugebauer P, Massih B, Göpfert MC, Heinrich R.

Front Mol Neurosci. 2019 Oct 11;12:251. doi: 10.3389/fnmol.2019.00251. eCollection 2019.

10.

Circulating Tumor Cell and Circulating Tumor DNA Assays Reveal Complementary Information for Patients with Metastatic Urothelial Cancer.

Chalfin HJ, Glavaris SA, Gorin MA, Kates MR, Fong MH, Dong L, Matoso A, Bivalacqua TJ, Johnson MH, Pienta KJ, Hahn NM, McConkey DJ.

Eur Urol Oncol. 2019 Sep 25. pii: S2588-9311(19)30130-0. doi: 10.1016/j.euo.2019.08.004. [Epub ahead of print]

PMID:
31563523
11.

Combined Next-generation Sequencing and Flow Cytometry Analysis for an Anti-PD-L1 Partial Responder over Time: An Exploration of Mechanisms of PD-L1 Activity and Resistance in Bladder Cancer.

Kates M, Nirschl TR, Baras AS, Sopko NA, Hahn NM, Su X, Zhang J, Kochel CM, Choi W, McConkey DJ, Drake CG, Bivalacqua TJ.

Eur Urol Oncol. 2019 Feb 26. pii: S2588-9311(19)30025-2. doi: 10.1016/j.euo.2019.01.017. [Epub ahead of print]

PMID:
31411999
12.

Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy.

Rosenberg JE, O'Donnell PH, Balar AV, McGregor BA, Heath EI, Yu EY, Galsky MD, Hahn NM, Gartner EM, Pinelli JM, Liang SY, Melhem-Bertrandt A, Petrylak DP.

J Clin Oncol. 2019 Oct 10;37(29):2592-2600. doi: 10.1200/JCO.19.01140. Epub 2019 Jul 29.

13.

Simvastatin and ML141 Decrease Intracellular Streptococcus pyogenes Infection.

Caffo L, Sneed BL, Burcham C, Reed K, Hahn NC, Bell S, Downham O, Evans MD, Fullenkamp CR, Drinnon TK, Bishop D, Bruns HA, McKillip JL, Sammelson RE, McDowell SA.

Curr Pharm Biotechnol. 2019;20(9):733-744. doi: 10.2174/1389201020666190618115154.

PMID:
31258074
14.

Role of Checkpoint Inhibition in Localized Bladder Cancer.

Hahn NM, Necchi A, Loriot Y, Powles T, Plimack ER, Sonpavde G, Roupret M, Kamat AM.

Eur Urol Oncol. 2018 Aug;1(3):190-198. doi: 10.1016/j.euo.2018.05.002. Epub 2018 May 30.

PMID:
31102620
15.

Tumor immune microenvironment in non-muscle-invasive urothelial carcinoma of the bladder.

Eich ML, Chaux A, Guner G, Taheri D, Mendoza Rodriguez MA, Rodriguez Peña MDC, Baras AS, Hahn NM, Drake C, Sharma R, Bivalacqua TJ, Rezaei K, Netto GJ.

Hum Pathol. 2019 Jul;89:24-32. doi: 10.1016/j.humpath.2019.04.003. Epub 2019 Apr 24.

PMID:
31026471
16.

Elucidating Non-aqueous Solvent Stability and Associated Decomposition Mechanisms for Mg Energy Storage Applications From First-Principles.

Seguin TJ, Hahn NT, Zavadil KR, Persson KA.

Front Chem. 2019 Apr 9;7:175. doi: 10.3389/fchem.2019.00175. eCollection 2019.

17.

A Global Deal For Nature: Guiding principles, milestones, and targets.

Dinerstein E, Vynne C, Sala E, Joshi AR, Fernando S, Lovejoy TE, Mayorga J, Olson D, Asner GP, Baillie JEM, Burgess ND, Burkart K, Noss RF, Zhang YP, Baccini A, Birch T, Hahn N, Joppa LN, Wikramanayake E.

Sci Adv. 2019 Apr 19;5(4):eaaw2869. doi: 10.1126/sciadv.aaw2869. eCollection 2019 Apr. Review.

18.

Oscillatory cortical forces promote three dimensional cell intercalations that shape the murine mandibular arch.

Tao H, Zhu M, Lau K, Whitley OKW, Samani M, Xiao X, Chen XX, Hahn NA, Liu W, Valencia M, Wu M, Wang X, Fenelon KD, Pasiliao CC, Hu D, Wu J, Spring S, Ferguson J, Karuna EP, Henkelman RM, Dunn A, Huang H, Ho HH, Atit R, Goyal S, Sun Y, Hopyan S.

Nat Commun. 2019 Apr 12;10(1):1703. doi: 10.1038/s41467-019-09540-z.

19.

Homocysteine-induced inverse expression of tissue factor and DPP4 in endothelial cells is related to NADPH oxidase activity.

Korkmaz HI, Hahn NE, Jansen KM, Musters R, van Bezu J, van Wieringen WN, van Zuijlen P, Ulrich M, Niessen H, Krijnen P.

Physiol Int. 2019 Mar 1;106(1):29-38. doi: 10.1556/2060.106.2019.05. Epub 2019 Mar 19.

PMID:
30888218
20.

The Microbiome and Genitourinary Cancer: A Collaborative Review.

Markowski MC, Boorjian SA, Burton JP, Hahn NM, Ingersoll MA, Maleki Vareki S, Pal SK, Sfanos KS.

Eur Urol. 2019 Apr;75(4):637-646. doi: 10.1016/j.eururo.2018.12.043. Epub 2019 Jan 15. Review.

PMID:
30655087
21.

Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes.

Grivas P, Mortazavi A, Picus J, Hahn NM, Milowsky MI, Hart LL, Alva A, Bellmunt J, Pal SK, Bambury RM, O'Donnell PH, Gupta S, Guancial EA, Sonpavde GP, Faltaos D, Potvin D, Christensen JG, Chao RC, Rosenberg JE.

Cancer. 2019 Feb 15;125(4):533-540. doi: 10.1002/cncr.31817. Epub 2018 Dec 20.

22.

CD24 regulates cancer stem cell (CSC)-like traits and a panel of CSC-related molecules serves as a non-invasive urinary biomarker for the detection of bladder cancer.

Ooki A, VandenBussche CJ, Kates M, Hahn NM, Matoso A, McConkey DJ, Bivalacqua TJ, Hoque MO.

Br J Cancer. 2018 Oct;119(8):961-970. doi: 10.1038/s41416-018-0291-7. Epub 2018 Oct 17.

23.

2-Aminobenzimidazoles as antibiofilm agents against Salmonella enterica serovar Typhimurium.

Huggins WM, Vu Nguyen T, Hahn NA, Baker JT, Kuo LG, Kaur D, Melander RJ, Gunn JS, Melander C.

Medchemcomm. 2018 Aug 2;9(9):1547-1552. doi: 10.1039/c8md00298c. eCollection 2018 Sep 1.

24.

SIU-ICUD recommendations on bladder cancer: systemic therapy for metastatic bladder cancer.

Merseburger AS, Apolo AB, Chowdhury S, Hahn NM, Galsky MD, Milowsky MI, Petrylak D, Powles T, Quinn DI, Rosenberg JE, Siefker-Radtke A, Sonpavde G, Sternberg CN.

World J Urol. 2019 Jan;37(1):95-105. doi: 10.1007/s00345-018-2486-1. Epub 2018 Sep 20. Review.

PMID:
30238401
25.
26.

NCCN Guidelines Insights: Bladder Cancer, Version 5.2018.

Flaig TW, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Downs TM, Efstathiou JA, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Jimbo M, Kader AK, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Petrylak DP, Plimack ER, Pohar KS, Porter MP, Preston MA, Sexton WJ, Siefker-Radtke AO, Tward J, Wile G, Johnson-Chilla A, Dwyer MA, Gurski LA.

J Natl Compr Canc Netw. 2018 Sep;16(9):1041-1053. doi: 10.6004/jnccn.2018.0072.

PMID:
30181416
27.

Naturally-occurring canine invasive urothelial carcinoma harbors luminal and basal transcriptional subtypes found in human muscle invasive bladder cancer.

Dhawan D, Hahn NM, Ramos-Vara JA, Knapp DW.

PLoS Genet. 2018 Aug 8;14(8):e1007571. doi: 10.1371/journal.pgen.1007571. eCollection 2018 Aug.

28.

Enhanced Stability of the Carba- closo-dodecaborate Anion for High-Voltage Battery Electrolytes through Rational Design.

Hahn NT, Seguin TJ, Lau KC, Liao C, Ingram BJ, Persson KA, Zavadil KR.

J Am Chem Soc. 2018 Sep 5;140(35):11076-11084. doi: 10.1021/jacs.8b05967. Epub 2018 Aug 21.

29.

Meridianin D Analogues Display Antibiofilm Activity against MRSA and Increase Colistin Efficacy in Gram-Negative Bacteria.

Huggins WM, Barker WT, Baker JT, Hahn NA, Melander RJ, Melander C.

ACS Med Chem Lett. 2018 May 25;9(7):702-707. doi: 10.1021/acsmedchemlett.8b00161. eCollection 2018 Jul 12.

30.

p47phox-Dependent Reactive Oxygen Species Stimulate Nuclear Translocation of the FoxO1 Transcription Factor During Metabolic Inhibition in Cardiomyoblasts.

Ter Horst EN, Hahn NE, Geerts D, Musters RJP, Paulus WJ, van Rossum AC, Meischl C, Piek JJ, Niessen HWM, Krijnen PAJ.

Cell Biochem Biophys. 2018 Sep;76(3):401-410. doi: 10.1007/s12013-018-0847-4. Epub 2018 Jun 29.

31.

Commentary on "Prognostic effect of carcinoma in situ in muscle-invasive urothelial carcinoma patients receiving neoadjuvant chemotherapy."

Thomas DE, Kaimakliotis HZ, Rice KR, Pereira JA, Johnston P, Moore ML, Reed A, Cregar DM, Franklin C, Loman RL, Koch MO, Bihrle R, Foster RS, Masterson TA, Gardner TA, Sundaram CP, Powell CR, Beck S, Grignon DJ, Cheng L, Albany C, Hahn NM.

Urol Oncol. 2018 Jul;36(7):345. doi: 10.1016/j.urolonc.2018.05.003. Epub 2018 Jun 5.

PMID:
29880459
32.

Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2).

Rosenberg JE, Hahn NM, Regan MM, Werner L, Alva A, George S, Picus J, Alter R, Balar A, Hoffman-Censits J, Grivas P, Lauer R, Guancial EA, Hoimes C, Sonpavde G, Albany C, Stein MN, Breen T, Jacobs C, Anderson K, Bellmunt J, Lalani AA, Pal S, Choueiri TK.

Br J Cancer. 2018 May;118(11):1434-1441. doi: 10.1038/s41416-018-0087-9. Epub 2018 May 16.

33.

Characterization of Urothelial Cancer Circulating Tumor Cells with a Novel Selection-Free Method.

Chalfin HJ, Kates M, van der Toom EE, Glavaris S, Verdone JE, Hahn NM, Pienta KJ, Bivalacqua TJ, Gorin MA.

Urology. 2018 May;115:82-86. doi: 10.1016/j.urology.2018.01.036. Epub 2018 Feb 9.

PMID:
29432873
34.

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial.

Kyriakopoulos CE, Chen YH, Carducci MA, Liu G, Jarrard DF, Hahn NM, Shevrin DH, Dreicer R, Hussain M, Eisenberger M, Kohli M, Plimack ER, Vogelzang NJ, Picus J, Cooney MM, Garcia JA, DiPaola RS, Sweeney CJ.

J Clin Oncol. 2018 Apr 10;36(11):1080-1087. doi: 10.1200/JCO.2017.75.3657. Epub 2018 Jan 31.

35.

Comparison of Pathological Stage in Patients Treated with and without Neoadjuvant Chemotherapy for High Risk Upper Tract Urothelial Carcinoma.

Liao RS, Gupta M, Schwen ZR, Patel HD, Kates M, Johnson MH, Hahn NM, McConkey D, Bivalacqua TJ, Pierorazio PM.

J Urol. 2018 Jul;200(1):68-73. doi: 10.1016/j.juro.2017.12.054. Epub 2018 Jan 4.

PMID:
29307680
36.

Contemporary Patterns of Multidisciplinary Care in Patients With Muscle-invasive Bladder Cancer.

Harshman LC, Tripathi A, Kaag M, Efstathiou JA, Apolo AB, Hoffman-Censits JH, Stadler WM, Yu EY, Bochner BH, Skinner EC, Downs T, Kiltie AE, Bajorin DF, Guru K, Shipley WU, Steinberg GD, Hahn NM, Sridhar SS.

Clin Genitourin Cancer. 2018 Jun;16(3):213-218. doi: 10.1016/j.clgc.2017.11.004. Epub 2017 Dec 6.

37.

Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel.

Harshman LC, Chen YH, Liu G, Carducci MA, Jarrard D, Dreicer R, Hahn N, Garcia JA, Hussain M, Shevrin D, Eisenberger M, Kohli M, Plimack ER, Cooney M, Vogelzang NJ, Picus J, Dipaola R, Sweeney CJ; ECOG-ACRIN 3805 Investigators.

J Clin Oncol. 2018 Feb 1;36(4):376-382. doi: 10.1200/JCO.2017.75.3921. Epub 2017 Dec 20.

38.

Phase 2 Trial of Gemcitabine, Cisplatin, plus Ipilimumab in Patients with Metastatic Urothelial Cancer and Impact of DNA Damage Response Gene Mutations on Outcomes.

Galsky MD, Wang H, Hahn NM, Twardowski P, Pal SK, Albany C, Fleming MT, Starodub A, Hauke RJ, Yu M, Zhao Q, Sonpavde G, Donovan MJ, Patel VG, Sfakianos JP, Domingo-Domenech J, Oh WK, Akers N, Losic B, Gnjatic S, Schadt EE, Chen R, Kim-Schulze S, Bhardwaj N, Uzilov AV.

Eur Urol. 2018 May;73(5):751-759. doi: 10.1016/j.eururo.2017.12.001. Epub 2017 Dec 13.

PMID:
29248319
39.

Incorporating DNA Methyltransferase Inhibitors (DNMTis) in the Treatment of Genitourinary Malignancies: A Systematic Review.

Chovanec M, Taza F, Kalra M, Hahn N, Nephew KP, Spinella MJ, Albany C.

Target Oncol. 2018 Feb;13(1):49-60. doi: 10.1007/s11523-017-0546-x.

40.

YAP1 and COX2 Coordinately Regulate Urothelial Cancer Stem-like Cells.

Ooki A, Del Carmen Rodriguez Pena M, Marchionni L, Dinalankara W, Begum A, Hahn NM, VandenBussche CJ, Rasheed ZA, Mao S, Netto GJ, Sidransky D, Hoque MO.

Cancer Res. 2018 Jan 1;78(1):168-181. doi: 10.1158/0008-5472.CAN-17-0836. Epub 2017 Nov 27.

41.

Lithium Self-Discharge and Its Prevention: Direct Visualization through In Situ Electrochemical Scanning Transmission Electron Microscopy.

Harrison KL, Zavadil KR, Hahn NT, Meng X, Elam JW, Leenheer A, Zhang JG, Jungjohann KL.

ACS Nano. 2017 Nov 28;11(11):11194-11205. doi: 10.1021/acsnano.7b05513. Epub 2017 Nov 13.

PMID:
29112807
42.

Low levels of PSMA expression limit the utility of 18F-DCFPyL PET/CT for imaging urothelial carcinoma.

Campbell SP, Baras AS, Ball MW, Kates M, Hahn NM, Bivalacqua TJ, Johnson MH, Pomper MG, Allaf ME, Rowe SP, Gorin MA.

Ann Nucl Med. 2018 Jan;32(1):69-74. doi: 10.1007/s12149-017-1216-x. Epub 2017 Oct 24.

43.

New bioactive glass scaffolds with exceptional qualities for bone tissue regeneration: response of osteoblasts and osteoclasts.

Kowal TJ, Hahn NC, Eider S, Marzillier JY, Fodera DM, Thamma U, Jain H, Falk MM.

Biomed Mater. 2018 Jan 24;13(2):025005. doi: 10.1088/1748-605X/aa9385.

PMID:
29033393
44.

Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology.

Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Clark PE, Downs TM, Efstathiou JA, Flaig TW, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Jimbo M, Kader AK, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Preston MA, Sexton WJ, Siefker-Radtke AO, Sonpavde G, Tward J, Wile G, Dwyer MA, Gurski LA.

J Natl Compr Canc Netw. 2017 Oct;15(10):1240-1267. doi: 10.6004/jnccn.2017.0156.

PMID:
28982750
45.

First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study.

Balar AV, Castellano D, O'Donnell PH, Grivas P, Vuky J, Powles T, Plimack ER, Hahn NM, de Wit R, Pang L, Savage MJ, Perini RF, Keefe SM, Bajorin D, Bellmunt J.

Lancet Oncol. 2017 Nov;18(11):1483-1492. doi: 10.1016/S1470-2045(17)30616-2. Epub 2017 Sep 26.

PMID:
28967485
46.

Once BCG Unresponsive, Always BCG Unresponsive: An Open Letter to the FDA to Enhance Recruitment into Clinical Trials in Bladder Cancer.

Kamat AM, Lerner S, Black P, Bellmunt J, Dinney C, Hahn NM, O'Donnell M, Quale DZ.

Bladder Cancer. 2017 Jul 27;3(3):145-146. doi: 10.3233/BLC-170118. No abstract available.

47.

Evaluation of different diagnostic methods for the detection of Mycobacterium avium subsp. paratuberculosis in boot swabs and liquid manure samples.

Hahn N, Failing K, Eisenberg T, Schlez K, Zschöck PM, Donat K, Einax E, Köhler H.

BMC Vet Res. 2017 Aug 18;13(1):259. doi: 10.1186/s12917-017-1173-6.

48.

Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study.

Powles T, O'Donnell PH, Massard C, Arkenau HT, Friedlander TW, Hoimes CJ, Lee JL, Ong M, Sridhar SS, Vogelzang NJ, Fishman MN, Zhang J, Srinivas S, Parikh J, Antal J, Jin X, Gupta AK, Ben Y, Hahn NM.

JAMA Oncol. 2017 Sep 14;3(9):e172411. doi: 10.1001/jamaoncol.2017.2411. Epub 2017 Sep 14.

49.

Preclinical Evaluation of Intravesical Cisplatin Nanoparticles for Non-Muscle-Invasive Bladder Cancer.

Kates M, Date A, Yoshida T, Afzal U, Kanvinde P, Babu T, Sopko NA, Matsui H, Hahn NM, McConkey DJ, Baras A, Hanes J, Ensign L, Bivalacqua TJ.

Clin Cancer Res. 2017 Nov 1;23(21):6592-6601. doi: 10.1158/1078-0432.CCR-17-1082. Epub 2017 Aug 14.

50.

The Insect Ortholog of the Human Orphan Cytokine Receptor CRLF3 Is a Neuroprotective Erythropoietin Receptor.

Hahn N, Knorr DY, Liebig J, Wüstefeld L, Peters K, Büscher M, Bucher G, Ehrenreich H, Heinrich R.

Front Mol Neurosci. 2017 Jul 14;10:223. doi: 10.3389/fnmol.2017.00223. eCollection 2017.

Supplemental Content

Support Center